Site Name:						
Comple CTC we	tigator Site File – document ve ete 'yes' or 'no' to confirm the presen ebsite: www.ctc.ucl.ac.uk.	ce or absence of each d				
	cument is missing and is not on the wo	Version	·	Present?	Comments	
	Document Name	version	Date	Presents	Comments	
01	CORRESPONDENCE & COMMUN	ICATION				
	Trial Newsletters: - Easter 2011 - Christmas 2011 - Easter 2012 - Christmas 2012 - Easter 2013 - Christmas 2013 - Christmas 2014 - MRD lab move & Newsletter May 2015	- - - - -	Mar2011 Dec2011 Mar2012 Dec2012 27mar13 Dec2013 Dec2014 15may15	Y		
	- Christmas 2015 - Spring 2017 - Summer 2018	- - -	02dec15 Apr2017 27Jun18	Y		
	UKALL14 Monitoring Plan	4.0	180ct16	Y 🔲 N 🔲		
	UKALL14 central monitoring checklists	-	-	Y N	Please file all previous versions of checklists here	
	UKALL14 Incident Report form	2.0	25jun15	Y 🔲 N 🔲		
02	CTC INFORMATION					
	CTC Contact List	7.0	29Aug18	Y 🔲 N 🔲		
03	PROTOCOL & AMENDMENTS:	Tick	to confirm previous	versions hav	e been superseded.	
	Current approved protocol	12	26Jun18	Y 🔲 N 🔲		
	Previously approved versions of protocol [v10 was never approved, rejected by MHRA]	11 9 8 7 (09.09.15 corrected 10.12.15) 7 6.1 6 5 4 3	11Sep17 17Feb17 12May16 10dec15 09sep15 27jan15 20jun14 20jul12 24apr12 18aug10 17may10	Y		
		1	11nov09	Y N		
04	PATIENT INFORMATION	Tick	to confirm previous	versions have	e been superseded.	
	Current approved PIS	10	28Jun18	Y N		
	UKALL14 Additional PIS - Suspension of palifermin	1	13apr16	Y N		
	UKALL14 Additional PIS – Drugs affecting ability to drive/operate machines	1.1	31Aug17	Y N		
	Patient Information Sheet/Consent Form – 'Registration only' sub-study	3	28Jun18	Y N		

**UKALL14** 

	Site Quality Control Checklists – Investigator Site File							
Site Name:								
Investigator Site File – document version checklist  Complete 'yes' or 'no' to confirm the presence or absence of each document specified. Most documents can be obtained from the CTC website: <a href="www.ctc.ucl.ac.uk">www.ctc.ucl.ac.uk</a> .  If a document is missing and is not on the website this will be provided to you for the ISF by UCL CTC following return of this checklist.								
	Document Name	Version	Date	Prese		Comments		
	Patient Information Sheet – Additional Genetic Testing – Buccal swab	1	09sep15	Y	N 🗌			
	Patient Information sheet – Additional Genetic Testing v1.0 – Stored Bone Marrow	1	09sep15	Y	N 🔲			
	GDPR Transparency Statement	1	11Jun18	Y 🔲	N 🗌			
	CTC GDPR Transparency Tracker	-	24May18	Y 🗌	N 🗌			
	Current approved Consent Form	1.2	29apr15	Y 🗌	N 🗌			
	Consent Form - Genetic Testing - Buccal swab v1.0 09.09.2015	1	09sep15	Y 🗌	N 🔲			
	Consent Form - Genetic Testing - Stored Bone marrow	1	09sep15	Y 🗌	N 🔲			
	Current approved GP Letter	1.0	11nov09	Y 🗌	N 🗌			
	Previously approved versions of PIS	9.0 8.0 7.0	11Sep17 09Aug17 17Feb17	Y	N			
		6.0 5.3 5.2	12May16 12May16 29apr15	Y	N			
		5.1 5	16jun14 13mar14	Y	N			
		4.1 4 3 2.1 2	16may13 01aug12 18aug10 17may10 24dec09		N			
	Previously approved versions of consent from	1 1.1	11nov09 03sep10	Υ□	N			
	Previously approved versions of 'Registration only' PIS	2	11Sep17	+=+	N 🔲			
	Patient Card	1.0	11nov09	Υ	N 🔲			
	Pregnancy Monitoring Information Sheet - patients	1.0	01aug12	Y 🗌	N 🔲			
	Pregnancy Monitoring Information Sheet - partners	1.0	01aug12	Y 🗌	N 🗌			
	Pregnancy Monitoring Consent Form - patients	1.0	01aug12	Υ	N 🗌			

1.0

1.0

1.1

Form - partners

**Pregnancy Monitoring Consent** 

Previously approved versions of

Sheet & consent form (reformatted)

**Pregnant Partner Information** 

N  $\square$ 

N

 $N \square$ 

01aug12

17may10

18aug10

Site N	Site Name:							
Inves	tigator Site File – document ve	ersion checklist						
	ete 'yes' or 'no' to confirm the presen		ocument specified. N	lost documents	s can be obtained from the			
	ebsite: <u>www.ctc.ucl.ac.uk</u> .							
	cument is missing and is not on the wo							
Section	Document Name	Version	Date	Present?	Comments			
05	ETHICS & REGULATORY APPROV	ALS *						
	*sites must have the initial approval lett	ers, site approval letter an	d all relevant subseque	nt approvals				
	Ethics approval letter (Main REC)	-	13jan10	Y N	]			
	MHRA approval letter	-	13jan10	Y 🔲 N 🗆	]			
	Sponsorship letter	-	25mar09	Y N	]			
	Letter of insurance from sponsor - initial	-	15may09	Y N	]			
	Letter of insurance from sponsor- subsequent years  Amendments- MHRA Approval Letters	PIS v2 Protocol v2 Protocol v3 Labelling Protocol v4 Protocol v5 Protocol v6 Protocol v6.1 Protocol v7 Protocol v8 Protocol v9 Protocol v11 Protocol v12	Aug09-10 Aug10-11 Aug11-12 Aug12-13 Aug13-14 Aug13-14 Aug14-15 Aug15-16 Aug15-16 Aug16-17 Aug17-18 Aug18-19 23feb10 21jun10 17sep10 03nov10 09may12 27sep12 15jul14 11mar15 15nov15 15Jun16 13Mar17 21Nov17 31Aug18	Y				
	Urgent Safety Measure	USM email -	24apr12	Y   N	Email correspondence sent from CTC 24.04.12 regarding USM			
	Correspondence	Protocol v4	401.15=	     	7			
	Rejection of Protocol v10 amendment Correspondence	-	12Jul17	Y N				
	Amendments - REC Approval Letters	Protocol v2 Protocol v3 Consent period Protocol v4 Protocol v5 PIS v4.0 PIS 4.1 PIS 5.0 Protocol v6 PIS v5.1 Protocol v6.1 PIS 5.2 ICF 1.2 Protocol v7 Protocol v8 Protocol v9	07jun10 08sep10 24aug11 16may12 23aug12 17may13 02apr14 09jul14 23feb15 21may15 30sep15 06Jun16 09Mar17	Y				

Site Name:						
Comple CTC we	tigator Site File – document vertee 'yes' or 'no' to confirm the present ebsite: <a href="www.ctc.ucl.ac.uk">www.ctc.ucl.ac.uk</a> .  Cument is missing and is not on the weather than the weather with the weather than the weather with the weather with the weather than the weather with the weather	ce or absence of each d				
	Document Name	Version	Date	ī	ent?	Comments
		PIS v8 Protocol v11 Protocol v12	05Sep17 30Oct17 27Jul18	Y	N	
06	AGREEMENTS & CONTRACTS					
	Clinical trial site agreement	-	-	Υ	N 🗌	
	Copy of site activation letter	-	-	Υ	N 🗌	
	First Amendment to CTSA	-	-	Y 🗌	N 🗌	As applicable
	Second Amendment to CTSA	-	-	Y 🔲	N 🗌	As applicable
07	SITE INFORMATION / SITE STAFF	INFORMATION				
	Site staff delegation log	1.0	08aug11	Y 🗌	N 🗌	
	Investigator Registration Forms	1.0	10aug11	Υ	N 🗌	
	Site Registration Form	1.0	04jul11	Y 🗌	N 🗌	
	Site initiation report & documentation (e.g. slides)	-	-	Y 🗌	N 🗌	
	UKALL14 Training Manual	1.0	27Nov17	Υ	N 🗌	
	UKALL14 'Registration only' Training Slides	1.0	15Nov17	Y 🗌	N 🗌	
	Other site visit reports (if applicable)	-	-	Y 🗌	N 🗌	
08	PATIENT SCREENING			•		
	Patient Screening Log	-	08dec10	Υ	N 🗌	
	Patient Screening Log Instructions	1.0	08dec10	Y 🗌	И	
	Patient log	1.0	08dec10	Υ	N 🗌	
	Site informed consent log	1	08dec11	Υ	N 🗌	
09	LABORATORY					
	Sample Request Form	5.0	23Nov17	Υ	N 🗌	+ file note dated 23Nov17
	Price List – UCL Adult ALL Lab	-	08aug10	Υ 🗌	N 🗌	
10	SUMMARY OF PRODUCTS CHARA	ACTERISTICS			I	
	Current versions of summary of products characteristics:  - Mabthera 500mg &100mg  - Kepivance  - Oncaspar	- - -	26Apr2018 May2013 Dec2017	Y	N	
	- Atriance	-	30Apr2018	Y   _	N 📙	
11	STUDY DRUG SUPPLIES / PHARM		46.4			n pharmacy file not ISF
	Drug Supply Guidelines	4.0	12Mar18	Υ	N _	
	Drug Accountability logs: - Phase 1 Oncaspar - Phase 1 Rituximab	2.0 2.0	18may15 18may15	Y	N N	

**UKALL14** 

Site (	Quality Control Checklists	<ul><li>Investigator S</li></ul>	ite File		
Site N	lame:				
Compl	tigator Site File – document ve ete 'yes' or 'no' to confirm the presend		document specified. M	ost documents o	can be obtained from the
	ebsite: <u>www.ctc.ucl.ac.uk</u> .	de de la latera de la colonia	-ll+	CL CTC falls.	. da a makuma af klada ah a al dhak
	cument is missing and is not on the we	· · · · · · · · · · · · · · · · · · ·	1		ving return of this checklist.
Section	Document Name	Version	Date	Present?	Comments
	<ul> <li>Phase 2 Nelarabine</li> <li>Consolidation Oncaspar</li> <li>Intensification Oncaspar</li> <li>Palifermin treatment</li> </ul>	2.0 2.0 2.0 2.0	18may15 18may15 18may15 18may15	Y N N Y N N N N N N N N N N N N N N N N	
	Stock Balance Logs: - Oncaspar - Rituximab - Nelarabine - Palifermin	1.0 1.0 1.0 1.0	18may15 18may15 18may15 18may15	Y	
	Drug order forms:  - Oncaspar - Rituximab - Nelarabine - Palifermin  UKALL14 memorandum to Investigators and Pharmacists	4 1 1 4	27Feb18 22Oct10 22Oct10 09sep15 26jan16	Y	
12	DATA MANAGEMENT				
12	DATA MANAGEMENT		<u> </u>		
	CRF – Registration	6.0	27nov15	Y	
	CRF – Cytogenetics	3.0	03may13	Y 🔲 N 🗀	
	CRF – Induction Treatment Phase 1	3.0	20apr15	Y 🔲 N 🗆	
	CRF – Induction Treatment Phase 2	3.0	20apr15	Y 🔲 N 🗀	
	CRF – Post Induction Treatment Allocation (PITA)	2.0	20apr15	Y 🔲 N 🗀	
	CRF – Post Induction Registration - Maintenance	2.0	20apr15	Y 🔲 N 🗀	
	CRF – Post Induction Registration- Transplant	2.0	20apr15	Y 🔲 N 🗀	
	CRF - Intensification	2.0	20apr15	Y 🔲 N 🗀	
	CRF - Consolidation	2.0	20apr15	Y 🔲 N 🗀	
	CRF – Transplant – incorporating the following forms:  - Conditioning (RIC/MAC)  - Palifermin  - ODMQ  - Transplant  - Day 100  - GvHD  - Graft failure  - Post-transplant	2.0	20apr15	Y  N  N	

1.0

08dec10

Υ[

Ν

assessment

CRF – Maintenance Treatment

**UKALL14** 

Site	Name:				
Inve Comp CTC w	stigator Site File – document ve blete 'yes' or 'no' to confirm the presen- vebsite: <u>www.ctc.ucl.ac.uk</u> .	ce or absence of each			
	ocument is missing and is not on the we	ebsite this will be prov	vided to you for the ISF b	y UCL CTC follor	wing return of this checklist.
Section	Document Name	Version	Date	Present?	Comments
	CRF - Relapse	2.0	19apr11	Y N	
	CRF – Centre Transfer	3.0	10mar16	Y N	
	CRF – Treatment Summary	4.0	27nov15	Y 🔲 N 🔲	
	CRF - Death	3.0	27nov15	Y N	
	CRF- Adverse Events (AEs) Forms - Induction Phase 1 - Induction Phase2 - Intensification - Consolidation - Transplant	3.0 3.0 3.0 3.0 3.0	27nov15 27nov15 27nov15 27nov15 27nov15	Y	
	CRF - Adverse Event of Special Interest – Thromboembolic Event Urgent Event Form	1	27nov15	Y	
	CRF – Annual Follow-up	2.0	20apr15	Y N	
	CRF – Late Effects	1.0	10mar16	Y 🔲 N 🔲	
	CRF – Annual Follow-up (Not in CR after Phase 2)	2.0	20apr15	Y N	
	CRF – Annual Follow-up (Relapse/Second Cancer)	2.0	20apr15	Y N	
	CRF – Second Cancer	2.0	20apr15	Y N	
	CRF – Lost to Follow-up	3.0	27nov15	Y 🗌 N 🗌	
	CRF - Informed Consent – Constitutional DNA	1	27nov15	Y N	
	CRF Completion Guidelines	5.0	14Mar18	Y N	
	CRF 'Registration only' Completion Guidelines	2.0	04Sep18	Y	
	CRF – 'Registration only' Substudy Entry	2.0	20Aug18	Y N	
	CRF – 'Registration only' Substudy Induction Treatment	2.0	20Aug18	Y N	
	CRF – 'Registration only' Substudy Post-Induction Chemotherapy	2.0	20Aug18	Y N	
	CRF – 'Registration only' Substudy GvHD	2.0	20Aug18	Y	
	CRF – 'Registration only' Substudy Transplant to D100	2.0	20Aug18	Y N	
	CRF – 'Registration only' Substudy Annual Follow -up	2.0	20Aug18	Y	
	SAE Form Guidance	4.0	23Nov17	Y N	

5.0

SAE Report Fax Header

SAE Report

Υ

23Nov17

Υ 🗌

N [

N  $\square$ 

Site N	Site Name:						
Comple CTC we	tigator Site File – document vo ete 'yes' or 'no' to confirm the preser ebsite: www.ctc.ucl.ac.uk. cument is missing and is not on the w	nce or absence of each of					
	<u>-</u>	Version	Date		ent?	Comments	
	SAE Report Additional Pages	1.0	08dec10	Υ	N $\square$		
	File Note: SAE Report v3 not disseminated	-	22jan16	Y 🗌	N 🗌		
	Pregnancy Report	3.0	23Nov17	Y 🗌	N 🗌		
	Pregnancy Report Additional Pages	1.0	08dec10	Y 🗌	N 🗌		
13	PHARMACOVIGILANCE				•		
	Safety updates/reports:  - SUSAR Quarterly Line Listings  Roche Six Monthly SUSAR	-	28aug12 10Jun-10Sep14 10Sep-10Dec14 11Dec-31Mar15 1Apr-30Jun15 01jul15-30sep15 01oct15-31dec15 01Jan16-31Mar16 01Apr16-30Jun16 01Jul16-30Sep16 01Oct16-31Dec16 01Jan17-31Mar17 01Apr17-30Jun17 01Jul17-30Sep17 01Oct17-31Dec17 01Jan18-31Mar18 01Apr18-30Jun18 26may-25nov13 26nov13-25may14 26may-17nov14	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y			
	reports		18nov14-17may15 18may15-17nov15	Y	N		
	Common terminology criteria for adverse events (CTCAE)	4.03	-	Υ	N 🗌		
14	REGULATORY GUIDELINES						
	Principles of ICH GCP	-	-	Υ	N		
	Declaration of Helsinki	-	Oct2008	Υ	N 📙		
supers has be	Previous versions of all documents listed above must be superseded. Please initial and date to confirm this action has been performed  Please provide the email address of the person to						
	n updated documents should be s						
This is	The completed form can be returned to <a href="mailto:ctc.ukall14@ucl.ac.uk">ctc.ukall14@ucl.ac.uk</a> or fax to 0207 679 9861 This is intended to support site's own internal systems for maintaining the ISF; therefore if the checklist is not returned to UCL CTC we will assume that documents contained within your ISF are up-to-date.						



#### Site Name:

#### Investigator Site File – document version checklist

Complete 'yes' or 'no' to confirm the presence or absence of each document specified. Most documents can be obtained from the CTC website: www.ctc.ucl.ac.uk.

If a document is missing and is not on the website this will be provided to you for the ISF by UCL CTC following return of this checklist.

Section Document Name Version Date Present? Comments

#### The following are general reminders regarding maintenance of the Investigator Site File:

The folder must be stored in a secure location with appropriate/restricted access.

The documents should be filed as per index.

(CTC index or site's own index is acceptable)

Documents generated locally (e.g. local approvals, lab normal ranges, correspondence, etc.) must be filed in the applicable sections.

Where documents are held in an alternative location, file notes should be present to indicate this.

Up-to-date CVs must be present for all site staff.

(CVs should be signed & dated and updated regularly according to employing institution policy)

GCP certificates must be present (or details of course attended listed in the CV) for all site staff.

(All staff should have attended a course — frequency of repeat training may be dictated by the employing institution policy, or 2 yearly where the institution has no policy, and more frequently when there have been updates to the legal or regulatory requirements for conduct of clinical trials)